The use of filgrastim in patients with hodgkin lymphoma receiving ABVD

Adam F. Binder, Sonia Rai, Amir Steinberg

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: There is conflicting data about the increased risk of pulmonary toxicity when granulocyte-stimulating factor (G-CSF) is given in combination with bleomycin. No clear consensus for management of patients with Hodgkin lymphoma (HL) who require G-CSF support exists. Our objective was to evaluate whether there is an increase in pulmonary toxicity in patients who receive bleomycin and G-CSF during treatment for HL. Materials and Methods: We conducted a single-center retrospective analysis of patients with Hodgkin Lymphoma from January 2003 until July 2015. All patients who received at least 1 dose of bleomycin and followed at our institution were included. Patients were evaluated for pulmonary toxicity starting from the day of first dose of bleomycin until 1 year after initiation of bleomycin. Data on pre-identified risk factors for pulmonary toxicity were also collected. Results: Fifty-four patients met inclusion criteria. Twenty-one patients received bleomycin alone, and 33 patients received bleomycin and G-CSF. There was no statistically significant (p = 0.50) difference in the development of pulmonary toxicity between the two groups. Crude hazard ratio for development of pulmonary toxicity in the bleomycin and G-CSF cohort was 1.58 (95% confidence interval, CI: 0.41-6.12). On multivariate analysis, the hazard ratio for development of pulmonary toxicity was 1.71 (95% CI: 0.43-6.81). Conclusion: This study does not find evidence that the combination of bleomycin and G-CSF increases the risk for bleomycin-induced pulmonary toxicity. We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.

Original languageEnglish (US)
Pages (from-to)286-292
Number of pages7
JournalInternational Journal of Hematology-Oncology and Stem Cell Research
Volume11
Issue number4
StatePublished - Jan 1 2017

Fingerprint

Bleomycin
Hodgkin Disease
Granulocytes
Lung
Filgrastim
Multivariate Analysis
Confidence Intervals

Keywords

  • Bleomycin
  • Bleomycin induced-pulmonary injury
  • Granulocyte stimulating factor
  • Hodgkin lymphoma
  • Treatment complications

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Transplantation

Cite this

The use of filgrastim in patients with hodgkin lymphoma receiving ABVD. / Binder, Adam F.; Rai, Sonia; Steinberg, Amir.

In: International Journal of Hematology-Oncology and Stem Cell Research, Vol. 11, No. 4, 01.01.2017, p. 286-292.

Research output: Contribution to journalArticle

Binder, Adam F. ; Rai, Sonia ; Steinberg, Amir. / The use of filgrastim in patients with hodgkin lymphoma receiving ABVD. In: International Journal of Hematology-Oncology and Stem Cell Research. 2017 ; Vol. 11, No. 4. pp. 286-292.
@article{8bbdf58df8d3465aabdfc8859be58ae1,
title = "The use of filgrastim in patients with hodgkin lymphoma receiving ABVD",
abstract = "Background: There is conflicting data about the increased risk of pulmonary toxicity when granulocyte-stimulating factor (G-CSF) is given in combination with bleomycin. No clear consensus for management of patients with Hodgkin lymphoma (HL) who require G-CSF support exists. Our objective was to evaluate whether there is an increase in pulmonary toxicity in patients who receive bleomycin and G-CSF during treatment for HL. Materials and Methods: We conducted a single-center retrospective analysis of patients with Hodgkin Lymphoma from January 2003 until July 2015. All patients who received at least 1 dose of bleomycin and followed at our institution were included. Patients were evaluated for pulmonary toxicity starting from the day of first dose of bleomycin until 1 year after initiation of bleomycin. Data on pre-identified risk factors for pulmonary toxicity were also collected. Results: Fifty-four patients met inclusion criteria. Twenty-one patients received bleomycin alone, and 33 patients received bleomycin and G-CSF. There was no statistically significant (p = 0.50) difference in the development of pulmonary toxicity between the two groups. Crude hazard ratio for development of pulmonary toxicity in the bleomycin and G-CSF cohort was 1.58 (95{\%} confidence interval, CI: 0.41-6.12). On multivariate analysis, the hazard ratio for development of pulmonary toxicity was 1.71 (95{\%} CI: 0.43-6.81). Conclusion: This study does not find evidence that the combination of bleomycin and G-CSF increases the risk for bleomycin-induced pulmonary toxicity. We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.",
keywords = "Bleomycin, Bleomycin induced-pulmonary injury, Granulocyte stimulating factor, Hodgkin lymphoma, Treatment complications",
author = "Binder, {Adam F.} and Sonia Rai and Amir Steinberg",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "286--292",
journal = "International Journal of Hematology-Oncology and Stem Cell Research",
issn = "1735-1243",
publisher = "Tehran University of Medical Sciences",
number = "4",

}

TY - JOUR

T1 - The use of filgrastim in patients with hodgkin lymphoma receiving ABVD

AU - Binder, Adam F.

AU - Rai, Sonia

AU - Steinberg, Amir

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: There is conflicting data about the increased risk of pulmonary toxicity when granulocyte-stimulating factor (G-CSF) is given in combination with bleomycin. No clear consensus for management of patients with Hodgkin lymphoma (HL) who require G-CSF support exists. Our objective was to evaluate whether there is an increase in pulmonary toxicity in patients who receive bleomycin and G-CSF during treatment for HL. Materials and Methods: We conducted a single-center retrospective analysis of patients with Hodgkin Lymphoma from January 2003 until July 2015. All patients who received at least 1 dose of bleomycin and followed at our institution were included. Patients were evaluated for pulmonary toxicity starting from the day of first dose of bleomycin until 1 year after initiation of bleomycin. Data on pre-identified risk factors for pulmonary toxicity were also collected. Results: Fifty-four patients met inclusion criteria. Twenty-one patients received bleomycin alone, and 33 patients received bleomycin and G-CSF. There was no statistically significant (p = 0.50) difference in the development of pulmonary toxicity between the two groups. Crude hazard ratio for development of pulmonary toxicity in the bleomycin and G-CSF cohort was 1.58 (95% confidence interval, CI: 0.41-6.12). On multivariate analysis, the hazard ratio for development of pulmonary toxicity was 1.71 (95% CI: 0.43-6.81). Conclusion: This study does not find evidence that the combination of bleomycin and G-CSF increases the risk for bleomycin-induced pulmonary toxicity. We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.

AB - Background: There is conflicting data about the increased risk of pulmonary toxicity when granulocyte-stimulating factor (G-CSF) is given in combination with bleomycin. No clear consensus for management of patients with Hodgkin lymphoma (HL) who require G-CSF support exists. Our objective was to evaluate whether there is an increase in pulmonary toxicity in patients who receive bleomycin and G-CSF during treatment for HL. Materials and Methods: We conducted a single-center retrospective analysis of patients with Hodgkin Lymphoma from January 2003 until July 2015. All patients who received at least 1 dose of bleomycin and followed at our institution were included. Patients were evaluated for pulmonary toxicity starting from the day of first dose of bleomycin until 1 year after initiation of bleomycin. Data on pre-identified risk factors for pulmonary toxicity were also collected. Results: Fifty-four patients met inclusion criteria. Twenty-one patients received bleomycin alone, and 33 patients received bleomycin and G-CSF. There was no statistically significant (p = 0.50) difference in the development of pulmonary toxicity between the two groups. Crude hazard ratio for development of pulmonary toxicity in the bleomycin and G-CSF cohort was 1.58 (95% confidence interval, CI: 0.41-6.12). On multivariate analysis, the hazard ratio for development of pulmonary toxicity was 1.71 (95% CI: 0.43-6.81). Conclusion: This study does not find evidence that the combination of bleomycin and G-CSF increases the risk for bleomycin-induced pulmonary toxicity. We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.

KW - Bleomycin

KW - Bleomycin induced-pulmonary injury

KW - Granulocyte stimulating factor

KW - Hodgkin lymphoma

KW - Treatment complications

UR - http://www.scopus.com/inward/record.url?scp=85030641635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030641635&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85030641635

VL - 11

SP - 286

EP - 292

JO - International Journal of Hematology-Oncology and Stem Cell Research

JF - International Journal of Hematology-Oncology and Stem Cell Research

SN - 1735-1243

IS - 4

ER -